Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Ipsen logo

Ipsen

Status

Completed

Conditions

Renal Cell Carcinoma Metastatic
Renal Cell Carcinoma

Study type

Observational

Funder types

Industry

Identifiers

NCT03699579
A-TW-60000-022

Details and patient eligibility

About

This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with confirmed diagnosis of clear-cell renal cell carcinoma
  • Patients with evidence of metastatic disease
  • Patients who have received at least one previous VEGFR-targeted therapy, i.e sunitinib, pazopanib or sorafenib
  • Patients who received care at the selected medical centers, utilizing the National Health Insurance (NHI) reimbursed system at the time of the disease

Exclusion criteria

  • Patients enrolled in any clinical trial involving anti-cancer therapy
  • Pregnant woman

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems